AL-ADTRAN
Adtran today launched its FSP 3000 M-Flex800™, enabling network operators to unlock the full potential of ZR and ZR+ optics for high-capacity transport solutions across edge, metro and core networks. This single-slot card – the newest addition to Adtran’s coherent optical technology suite – offers a universal host for ZR and ZR+ optics and addresses many of the shortfalls of IP-over-DWDM (IPoWDM) solutions. Compared to classical OTN muxponder solutions, M-Flex800™ supports much simpler demarcation and multiplexing technology. Combined with the use of a wide range of ZR optics, this enables a new way to develop compact and low-power transport solutions from the edge to the core. This new IP-to-DWDM approach enables flexible, cost-efficient networking with separated IP and optical layers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321282596/en/
Adtran’s FSP 3000 M-Flex800™ is a one-slot card that acts as a universal host for ZR, ZR+ and OpenROADM coherent interfaces. (Photo: Business Wire)
“Initially developed for DCI, ZR optics are now expanding their reach into diverse operational environments. Today’s launch will be key in that transition. Our new FSP 3000 M-Flex800™ will be a gateway between classical DWDM and the latest IPoDWDM, bringing the benefits of standardized ZR optics to a broad spectrum of operators,” said Christoph Glingener, CTO of Adtran. “Our versatile one-slot card acts as a universal host for ZR, ZR+ and OpenROADM coherent interfaces, seamlessly integrating into any open line system and enabling multiple use cases. Whether you’re looking to deploy in carrier infrastructure or DCI environments, in central offices or street cabinets, our M-Flex800™ can be easily slotted into any FSP 3000 chassis.”
The Adtran FSP 3000 M-Flex800™ is a versatile, multi-rate line card able to support an extensive range of grey and coherent interfaces, including 100Gbit/s, 400Gbit/s, 800Gbit/s, ZR, ZR+, OpenROADM and other types of coherent optics. Designed to meet the high-capacity connectivity needs of telecom operators, cloud providers and enterprises, it facilitates a range of applications from the edge to the core. This universal host simplifies upgrades to 800Gbit/s line speeds and Ethernet services and can multiplex 100GbE, 400GbE and OTU4 services into line speeds up to 800Gbit/s. Suited for tasks such as IP and optical demarcation, ZR-to-ZR interconnects and edge OTN applications, the Adtran FSP 3000 M-Flex800™ offers a cost-effective and low-power solution in a single-slot card.
“With its exceptional flexibility, operational simplicity and compact footprint, our FSP 3000 M-Flex800™ caters to diverse environments, from data centers to space-restricted street cabinets. Its ability to reduce power consumption while supporting high-capacity, open and scalable transport is a testament to our commitment to driving the next generation of transport infrastructure,” commented Ryan Schmidt, GM of optical transport at Adtran. “We’re addressing the core needs of network operators across a broad spectrum of applications, even beyond the traditional transponder/muxponder use cases. Today’s launch marks a big step towards more efficient, versatile and cost-effective infrastructure.”
Further information on the FSP 3000 M-Flex800™ is available in these slides.
A supporting product video is also available to watch.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321282596/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom